Evidence map›Paper›PMID 28539490›Full record

ArticleArteriosclerosis, thrombosis, and vascular biology2017

Quality Versus Quantity: Making HDL Great Again.

Sylvain Galvani, Timothy Hla

Abstract readEditorialComment
In one paragraph

Article in Arteriosclerosis, thrombosis, and vascular biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Article
  3. Understanding HDL Metabolism and Biology Through In Vivo Tracer Kinetics.Arteriosclerosis, thrombosis, and vascular biology · 2024
    Review
  4. Review
  5. Review
  6. Review
  7. Cardiovascular Immunotherapy and the Role of Imaging.Arteriosclerosis, thrombosis, and vascular biology · 2017
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Sylvain GalvaniFrom the Vascular Biology Program, Boston Children's Hospital, MA (S.G., T.H.); and Department of Surgery, Harvard Medical School, Boston, MA (S.G., T.H.).
Timothy HlaFrom the Vascular Biology Program, Boston Children's Hospital, MA (S.G., T.H.); and Department of Surgery, Harvard Medical School, Boston, MA (S.G., T.H.). Timothy.Hla@childrens.harvard.edu.

Funding

Mechanisms of sphingolipid signaling in vascular health and diseaseR35HL135821 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI HLA, TIMOTHY TUN · 2017 to 2023
$6.3M
NHLBI NIH HHS R35 HL135821
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Diabetes Mellitus, Type 1Anti-Inflammatory AgentsApolipoproteins MFemaleHumansLysophospholipidsAnti-Inflammatory AgentsApolipoproteins MAPOM protein, humanLysophospholipidsapolipoprotein A-Iapolipoprotein McholesterolEditorialslipoproteins, HDLproteomesphingosine 1-phosphateultracentrifugation

Identifiers

PMID28539490
PMCPMC5498076

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.